Table 1

Contribution of individual treatments to the fall in coronary heart disease mortality in Scotland, 1975 to 1994. Deaths prevented or postponed as a result of treatments

TreatmentsPatients eligibleUptake of interventionAbsolute risk reductionDeath prevented or postponed1-150 Proportion of overall deaths prevented or postponed
Acute MI155050.069694  (366–1083)10%
 Community CPR63570.50.056178 (168–188)
 Hospital CPR13550.950.150193 (55–271)
 Thrombolysis alone121810.010.0304 (1–18)
 Thrombolysis and aspirin121810.30.52190 (88–369)
 Aspirin alone121810.290.02485 (33–148)
 ACE inhibitor121810.160.006513 (5–30)
 β Blocker121810.20.01332 (16–59)
Secondary prevention post-MI361960.019431 (152–877)6%
 Aspirin alone361960.550.00797 (22–177)
 β Blocker alone361960.150.02394 (23–55)
 Aspirin and β blocker361960.050.02939 (42–218)
 ACE inhibitor361960.100.02362 (11–222)
 Simvastatin361960.100.00617 (2–59)
 Warfarin361960.050.01015 (3–50)
 Rehabilitation including exercise361960.190.020117 (43–258)
Secondary prevention post-CABG/angioplasty112670.750.019114 (49–243)2%
Angina1567510.004329 (36–686)5%
 CABG surgery133841.000.010131 (95–387)
 Angioplasty61141.000.00212 (0–26)
 Unstable angina64501.000.00534 (4–90)
 Aspirin in community1567510.330.004152 (32–570)
Heart failure 76978563 (489–617)8%
 Hospital95620.400.125333 (105–738)
 Community769780.200.030362 (38–1316)
Hypertension19352000.620.003590 (150–1132)9%
Total treatments2722 (1373–5986)40%
  • 1-150 Minimum and maximum estimates.

  • MI, myocardial infarction; CPR, cardiopulmonary resuscitation.